BioCentury
ARTICLE | Finance

Iterating iTeos

How an MPM-led series B aligns iTeos for a potential IPO

June 20, 2018 1:38 AM UTC

With a new office in the U.S. and $75 million in fresh series B funding to support clinical development of at least two candidates, Belgian cancer company iTeos Therapeutics S.A. is considering a U.S. IPO as its next big step.

MPM Capital led iTeos’ new round, which also included HBM Partners, 6 Dimensions Capital, Curative Ventures and SFPI as well as existing investors Fund+, Vives Louvain Technology Fund, Société Régionale d’Investissement de Wallonie (SRIW) and Pfizer Inc. (NYSE:PFE). iTeos previously raised €3 million ($4 million) in a 2012 series A round, and added another €1.4 million from Pfizer and SRIW in 2014...